Circio Holding ASA (CRNA) - tidl: Targovax (TRVX) 1

[RubenAyala]

(hva er status CRNA+Valo ? still alive and kicking ?)

[aborum]

– The type of RNA that is receiving the most investment right now is circular RNA, and Circio is the most advanced company in Europe in circRNA technology. We have developed a circRNA concept that has demonstrated a 15x extended shelf life compared to mRNA, says Erik Digman Wiklund, CEO of Circio.

Så fremstår det at se om det forbliver hyldevare, eller om circRNA udtrykket kan opretholdes i tilsvarende længde in vivo.

[RubenAyala]

Interessant og forklarende i forhold til kompetansen i selskapet og jump-starten av de prekliniske undersøkelsene. T.B. Hansen ble engasjert som konsulent tidlig 2H-2021, og ansatt som VP fra 1H-2022. Det som kanskje ikke er like godt kjent er at Eoghan T. Oleary (nå Director RNA Research i Circio) tok sin PhD ved universitet i Aarhus, og har utgitt en del publikasjoner om circRNA sammen med T.B.Hansen siden 2020 og frem til i dag.

Eoghan O'Leary - Director RNA Research at Targovax | The Org

[nordpolen]

Det begynner å lukte litt fugl her nå

[aborum]

… melt up imminent, jeg kan mærke det på mine striber …

[Moborg]

[Bompiole]

Det kunna vør verre kjære medaksjonærer vi kunne hatt aksjer i SAS

[TekBot]

Circio Holding ASA - Ex. reverse share split today

· Issuer name: Circio Holding ASA
· Ex. date: 4 October 2023
· Type of corporate action: reverse share split
…

Vis børsmeldingen

· Other information: reverse split ratio - thirty (30) old shares give one (1)
new share
· New par value per share: NOK 0.6
· New ISIN: NO0013033795
· New number of shares outstanding: 7,163,743

This information is published in accordance with the requirements of the
Continuing Obligations.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com (erik.wiklund@targovax.com)

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@circio.com (renate.birkeli@targovax.com)

Kilde

[TekBot]

Circio invites to a company update on Wednesday 11 October 2023

Oslo, Norway, 4 October 2023 - Circio Holding ASA (OSE: CRNA): Circio’s
management invites to a live webcast on Wednesday 11 October at 10am CEST. In
the webcast, CEO Dr. Erik D. Wiklund and VP and Head of Research Dr. Thomas B.
…

Vis børsmeldingen

Hansen will provide an overview of recent circRNA data and an update on the
development strategy. The presentation will be followed by a Q&A session.

Date: Wednesday 11 October 2023
Time: 10.00 CEST
Webcast Click here for teams
link: link (https://bit.ly/3ZHNYyD)
Presenters: Erik Digman Wiklund, CEO, Thomas
Birkballe Hansen, VP and Head of
Research

Please submit any questions in advance to renate.birkeli@circio.com or directly
during the live webcast.

Questions can be made in English or Norwegian and will be addressed in the
respective language.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com (erik.wiklund@targovax.com)

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@circio.com (renate.birkeli@targovax.com)

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA and
immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform to develop novel
circRNA medicines for cancer, vaccines, rare disease, protein replacement
therapy and cell therapy. The proprietary circVec technology is based on a
modular genetic cassette design for efficient biogenesis of multifunctional
circRNA that can be deployed for many purposes. The most advanced concept,
circAde, builds on the company´s validated adenovirus platform to deliver
circRNA for durable expression of therapeutic proteins directly into cancer
cells. This unique approach is the only currently known circRNA program capable
of targeting solid tumors. The circVec platform has broad potential
applications, and Circio´s strategy is to generate one or more lead candidates
for in house development in specific disease indications and in parallel seek
partnerships for other technical applications and therapeutic areas. The circRNA
R&D activities are being conducted by the wholly owned subsidiary Circio AB
based at the Karolinska Institute in Stockholm, Sweden.

In addition to Circio’s circRNA program, the Company’s’ clinical stage
immunotherapy programs are designed to activate the patient´s own immune system
to fight cancer cells and provide benefit to patients with no or few treatment
alternatives. ONCOS-102 has demonstrated an excellent safety profile, strong
immune responses and clinical efficacy in several cancer types in Phase 1/2
studies, both as monotherapy and in combinations with checkpoint inhibitors or
standard-of-care chemotherapy. A phase 2 trial to confirm the therapeutic
activity of ONCOS-102 in melanoma patients resistant to PD-1 checkpoint
inhibitor treatment has been designed, and Circio is seeking external financing
and/or partnerships to continue the clinical development.

Circio’s second clinical stage program is an immunotherapy targeting KRAS driver
mutations. TG01 has previously shown robust immune responses and encouraging
clinical benefit in surgically resected pancreatic cancer and is currently being
tested in two clinical trials in RAS-mutated pancreatic cancer and multiple
myeloma in the USA and Norway. These studies are being run through academic
collaborative networks, supported by prestigious research grants from Innovation
Norway and the Norwegian Research Council, creating broad future optionality for
the TG01 program at low cost to Circio.

Kilde

[Aagaard1]

Det skal blive interessant

[Celestar]

Håper virkelig de har noe fornuftig å komme med denne gangen. Tidligere «oppdateringer fra selskapet» har vært så nå bør de levere!!!

[nordpolen]

Data og strategi.

Regner med de henger veldig tett sammen.

Uansett; det blir himmel eller helvete

[RubenAyala]

IND Kina + gode/mindre godt nytt om fremdrift cRNA + endring management/ekstern bistand kommersielle avtaler (LG deltar ikke, og oppgis ikke som IR-kontakt på meldingen eller på “About us” på hjemmesiden ?).

edit: LG fortsatt oppgitt sammen med Renate under Investors og Media. Så kanskje litt kjapp der.

[Bompiole]

Hmm, LG på vei ut da??eller fryktelig optatt?

[Domboshawa]

Circio has established a unique circular RNA (circRNA) platform to develop novel circRNA medicines for cancer.
Kan ikke skjønne annet enn at dette må gå til himmels!

[Boms]

Det samme stod i børsmeldingen den 28 september, har ikke sjekket lengre tilbake, men helt nytt er det ikke. Men det er spennende om de kommer med noe håndfast og med en tidslinje for et videre løp.

@TekBot

Circio Holding ASA is a biotechnology company developing novel circular RNA and
immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform to develop novel
circRNA medicines for cancer, vaccines, rare disease, protein replacement
therapy and cell therapy. The proprietary circVec technology is based on a
modular genetic cassette design for efficient biogenesis of multifunctional
circRNA that can be deployed for many purposes.

[Xon]

[Celestar]

Spennende å se hvordan markedet reagerer på reverse split. Går vi under 10kr i dag?

[Bompiole]

eller opp?

[RubenAyala]

Atlas har nå ca 470.000 aksjer i sin beholdning. Endringene i avtalen er vel primært gjort for at exit/salg kan skje i et større tempo dersom det er ambisjonen. Av det så følger det neppe kursoppgang på kort sikt. Og det er vel også normalen etter en slik splitt.